


3rd Quarter 2023 Report (July 1 – September 30)

Percent change evaluated relative to 3rd Quarter 2022

Summary

- The percentage of prescribers enrolled in the PDMP system has stayed consistent compared to the 3rd quarter of 2022 (*Figure 1 and Table 1*).
- Total Gateway automated queries decreased (-8.9%) while reports viewed increased (1.9%). Web queries also increased (4.9%) compared to 3rd quarter of 2022 (*Table 3*).
- Overall, the total number of prescriptions for controlled substances have increased (1.6%) compared to the 3rd quarter of 2022. Gabapentin is the most prescribed substance in the system with a slight increase (0.2%) in prescriptions over Q3 2022. Stimulant prescriptions continue to increase with amphetamine prescriptions up 4.2% and methylphenidate prescriptions increasing 13.1% (*Table 5*).



- *Figure 1* shows the percentage of PDMP-enrolled prescribers over time from 2013-2023. Registration has remained high since 2018, especially among top prescribers.

Table 1. PDMP Enrollment and System Use for Oregon Prescribers¹: July 1– Sept. 30, 2023.

User Type	Prescribers	Enrolled	Web Query	Automated Query	Total Query
All Prescribers (by DEA)	19,164	16,558 (86.4%)	3,541 (21.4%)	12,644 (76.4%)	13,438 (81.2%)
Top 4,000 Prescribers	4,000	3,936 (98.4%)	1,602 (40.7%)	3,543 (90.0%)	3,737 (94.9%)
Top 2,000 Prescribers	2,000	1,981 (99.1%)	922 (46.5%)	1,809 (91.3%)	1,904 (96.1%)

¹Counts provided by unique DEA number, but providers may have multiple DEA numbers.

- Controlled substances were prescribed by 19,164 Oregon providers in Q3 of 2023.
- During the 3rd quarter, 81.2% of enrolled prescribers, 94.9% of the top 4,000 prescribers, and 96.1% of the top 2,000 prescribers used the web portal or Gateway integration.
- The total percentage of enrolled prescribers querying was 81.2%. This has remained consistent since the 3rd quarter of last year when 81.3% of users queried.

Table 2. Special Requests: July 1 – September 30, 2023.

Measure	Count
Patient Records	18
Healthcare Boards	35
Law Enforcement	15
Total Special Requests	68

- 68 special requests were received and processed by PDMP staff.
- Healthcare boards continue to be the most frequent originators of these requests.

Table 3. PDMP Activity Summary Statistics: July 1 – September 30, 2023.

User Type	Web Portal		Gateway Integration			
	Queries ¹	% Change ²	Automated Queries ¹	% Change ²	Reports Viewed ¹	% Change ²
Healthcare providers	82,598	-3.7%	5,160,339	-11.0%	823,714	-5.0%
Pharmacies	93,288	6.0%	1,176,570	1.7%	656,384	12.2%
Delegates	163,927	9.1%	-	-	-	-
Queries²	339,894	4.9%	6,336,909	-8.9%	1,480,098	1.9%

¹Query data drawn from AWARe web portal, PMPi Gateway audit file and EDIE supplementary audit file. Queries de-duplicated using last name, date of birth, prescriber ID, and query date.

²Percent change evaluated relative to same quarter the prior year.

- Overall, web queries increased over the last year with the largest increase from delegates. Usage from healthcare providers decreased for both web portal and gateway integration, while pharmacy usage increased.

Table 4. Query by Clinical User Group for Enrolled Providers: July 1 – Sept. 30, 2023.

Discipline	Total Accounts (by DEA) ¹	% Change ²	Web User ³	% Change ²	Integrated User ³	% Change ²
MD/PA/DO	20,506	10.4%	1,613	-1.1%	14,343	-2.7%
NP/CNS-PP	4,916	8.4%	1,100	10.8%	3,365	-2.1%
RPh	3,347	9.4%	1,385	3.1%	467	8.9%
Delegates	3,141	12.7%	1,796	10.9%	NA	NA
DDS/DMD	2,698	2.6%	364	-9.0%	281	7.3%
ND	556	-3.6%	166	6.4%	354	-23.5%

¹Counts provided by unique DEA Number, but providers may be associated with multiple DEA numbers.

²Percent change evaluated relative to same quarter during the prior year.

³Query data drawn from Appriss AWARe web portal, PMPi Gateway audit file and EDIE supplementary audit file. Queries de-duplicated using last name, date of birth, prescriber ID, and date of query.

- In general, enrollment has increased among all except ND disciplines. The greatest increases were in MD/PA/DO (10.4%) and Delegate (12.7%) disciplines over Q3 2022.
- The MD/PA/DO discipline decreased both web portal and integrated usage. Delegates increased usage of the web portal 10.9% over Q3 2022.

Table 5. Top Prescriptions: July 1 – September 30, 2023.

Drug	Number of Rx	% of all Rx	% Change
All	1,673,123	100%	1.6%
Gabapentin	237,763	14.2%	0.2%
Oxycodone	222,739	13.3%	-0.3%
Amphetamine	214,457	12.8%	4.2%
Hydrocodone	208,020	12.4%	-6.8%
Methylphenidate	93,287	5.6%	13.1%
Lorazepam	80,616	4.8%	-1.3%
Tramadol	75,385	4.5%	-3.8%
Zolpidem	59,780	3.6%	-4.1%
Testosterone	56,728	3.4%	11.9%
Alprazolam	55,913	3.3%	-4.0%

- Overall, the number of prescriptions increased 1.6% relative to the 3rd quarter of 2022.
- Gabapentin is the top prescribed drug in the PDMP (14.2% of all prescriptions) with a 0.2% increase in prescribing relative to Q3 2022. The addition of gabapentin as a PDMP-covered substance was effective as of January 1st, 2020.
- Prescriptions for the stimulants amphetamine and methylphenidate increased by 4.2% and 13.1% relative to the same quarter last year.

Note: Naloxone prescriptions are no longer collected by the PDMP as of September 2023.

Contact: PDMP Research Analyst, pdmp.research@odhsoha.oregon.gov
